Immunocytokines: A new approach to immunotherapy of melanoma

Melanoma Research

Volumn 7, Issue SUPPL. 2, 1997, Pages

  Reisfeld, Ralph A ^a   Becker, Jürgen C ^c   Gillies, Stephen D ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Fuji ImmunoPharmaceuticals Corp   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Immunocytokines; Melanoma; Targeted interleukin 2 therapy

Indexed keywords

INTERLEUKIN 2;

ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; HUMAN; MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE; TARGET CELL;

ANIMALS; CYTOKINES; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; INTERLEUKIN-2; MELANOMA; MICE; T-LYMPHOCYTES;

EID: 0030771674     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Talmage DW, Woolnough JA, Hemmingsen H, et al. Activation of cytotoxic T cells by non-stimulating tumor cells and spleen cell factor(s). Proc Natl Acad Sci U S A 1977; 74:4610-4614.
2. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interlenkin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988; 319:1676-1680.
3. Winkelhake JL, Gauny SS. Human recombinant interleukin-2 as an experimental therapeutic. Pharm Rev 1990; 42:1-64.
4. Maas RA, Dullens HFJ, Otter WD. IL-2 in cancer treatment. Cancer Immunol Immunother 1993; 36:141-148.
5. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995; 13:399-415.
6. Schmidt-Wolf G, Schmidt-Wolf IGH. Cytokines and clinical gene therapy. Eur J Immunol 1995; 25:1137-1140.
7. Dranoff G, Mulligan RC. Gene transfer as cancer treatment. Adv Immunol 1995; 58:417-454.
8. Gillies SD, Young D, Lo K-M, et al. Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD antibody. Hybridoma 1991; 3:347-356.
9. Reisfeld RA, Gillies SD. Recombinant antibody fusion proteins for cancer immunotherapy. In Current Topics in Microbiology and Immunology: Therapeutic Approaches for Metastasis Treatment. Edited by Gunthert U, Birchmeier W. Berlin: Springer Verlag, 1996.
10. Gillies SD, Reilly EB, Lo K-M, et al. Antibody-targeted interleukin 2 stimulates T cell killing of autologous tumor cells. Proc Natl Acad Sci USA 1992; 89:1428-1432.
11. Naramura M, Gillies SD, Mendelsohn J, et al. Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL-2 fusion protein against human melanoma cells. Immunol Lett 1994; 39:91-99.
12. Becker JC, Pancook JD, Gillies SD, et al. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc Natl Acad Sci U S A 1996; 93:2702-2707.
13. Mueller BM, Romerdahl CA, Gillies SD, et al. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD antibody. J Immunol 1990; 144:1382-1386.
14. Becker JC, Varki NM, Gillies SD, et al. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Natl Acad Sci U S A 1996; 93:7826-7831.
15. Becker JC, Pancook JD, Gillies SD, et al. T cell mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 1996; 183:2361-2366.
16. Haraguchi M, Yamashiro S, Yamamoto A, et al. Isolation of GD3 synthase gene by expression cloning of GM3 α-2,8-sialtransferase cDNA using anti-GD monoclonal antibody. Proc Natl Acad Sci U S A 1994; 91:10455-10459.
17. Ehrlich P. The Croonian lecture: on immunity. Proc R Soc Lond [Biol] 1900; 66:424-437.
18. George AJT, Spooner RA, Epenetos AA. Applications of monoclonal antibodies in clinical oncology. Immunol Today 1994; 15:559-561.
19. Goldenberg DM, Larson SM, Reisfeld RA, et al. Targeting cancer with radiolabeled antibodies. Immunol Today 1995; 16:261-264.
20. Ghetie M-A, Vitetta ES. Recent developments in immunotoxin therapy. Curr Opin Immunol 1991; 6:707-714.
21. Jurcic JG, Scheinberg DA. Recent developments in the radioimmunotherapy of cancer. Curr Opin Immunol 1994; 6:715-721.
22. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T-helper function in the generation of an anti-tumor response. Cell 1990; 60:397-403.
23. Abdel-Wahab Z, Li WP, Osanto S, et al. Transduction of human melanoma cells with interleukin-2 gene reduces tumorgenicity and enhances host anti-tumor immunity: a nude mouse model. Cell Immunol 1994; 159:26-39.
24. Zatloukal K, Schneeberger A, Berger M, et al. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. J Immunol 1995; 154:3406-3419.
25. Bannerji R, Arroyo CD, Cordon-Cardo C, et al. The role of IL-2 secreted from genetically modified tumor cells in the establishment of anti-tumor immunity. J Immunol 1994; 152:2324-2332.
26. Hara I, Nguyen H, Takechi Y, et al. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. Int J Cancer 1995; 61:253-260.
27. Maass G, Schmidt W, Berger M, et al. Priming of tumor-specific T cells in the draining lymph nodes after immunization with IL-2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sci U S A 1995; 92:5540-5544.
28. Mackay CR. T cell memory: the connection between function, pheno- type and migration pathways. Immunol Today 1991; 12:189-193.
29. Gansbacher B, Zier K, Daniels B, et al. Interleukin-2 gene transfer into tumor cells abrogates tumorgenicity and induces protective immunity. J Exp Med 1990; 172:1217-1224.
30. Cavallo F, Giovarelli M, Gulino A, et al. Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma-made immunogenic by IL-2 gene. J Immunol 1992; 149:3627-3635.
31. Kündig TM, Bachmann MF, DiPaolo C, et al. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 1995; 268:1343-1347.
32. Sprent J. Professionals and amateurs. Curr Biol 1995; 5:1095-1097.
33. Burg G, Dummer R, Becker JC. The skin as a target organ during IL-2 administration. In Basic Mechanisms of Physiologic and Aberrant Lymphoproliferation in the Skin. Edited by Lambert WC. New York: Plenum Press, 1994:451-458.
34. Steinman RM. The dentritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9:271-307.
35. Herrmann F, Cannistra SA, Levine H, et al. Expression of interleukin-2 receptors and binding of interleukin-2 by gamma interteron induced human leukemic and normal monocytic cells. J Exp Med 1985; 162:1111-1116.
36. Strobel I, Rupee R, Wollenberg A, et al. IL-2 receptor on human Langerhans cells lack the β-chain, but mediates IL-2-dependent migration: evidence for a putative γ-chain? Arch Dermatol Res 1993; 285:108.
37. Bevan MJ. Antigen presentation to cytotoxic T lymphocytes in vivo. J Exp Med 1995; 182:639-641.